Literature DB >> 7529547

Identification, molecular cloning, and characterization of the chromosome 12 breakpoint cluster region of uterine leiomyomas.

E F Schoenmakers1, R Mols, S Wanschura, P F Kools, J M Geurts, S Bartnitzke, J Bullerdiek, H van den Berghe, W J Van de Ven.   

Abstract

Recent molecular cytogenetic analysis of uterine leiomyoma cell lines with chromosome 12 aberrations has indicated that their chromosome 12 breakpoints map between linkage locus D12S8 and the CHOP gene. Here, we report fluorescence in situ hybridization (FISH) and molecular cloning studies of the chromosome 12 breakpoints in a panel of seven such uterine leiomyoma cell lines; five with the frequently observed t(12;14)(q15;q24), one with t(12;15)(q15;q24), and one with ins(12;11)(q14;q21qter). Directional chromosome walking studies starting from D12S8 and the CHOP gene resulted in the isolation of a relatively large number of overlapping YAC clones, including Y5355 (465 kbp), Y7673 (360 kbp), and Y9899 (275 kbp). In total, the inserts of these three YAC clones span an 800 kbp long and presumably contiguous stretch of human genomic DNA. All chromosome 12 breakpoints of the uterine leiomyoma cell lines studied were found by FISH analysis to be mapping within a 445 kbp subfragment of this region and, furthermore, to be dispersed over a DNA region which is at least 150 kbp in size. The chromosome 12 breakpoint of t(12;14)(q15;q24) in uterine leiomyoma cell line LM-30.1/SV40 was tentatively mapped within the 60 kbp region between YAC clones Y9899 and Y5355. From this 60 kbp region and close to sequence-tagged site RM99, we isolated probe pRM118-A, which showed in Southern blot analysis that it detected a rearrangement in LM-30.1/SV40 DNA, and generated restriction maps of the normal and rearranged genomic DNA regions detected with this probe. Finally, we molecularly cloned part of one of those rearranged DNA fragments using a vectorette-PCR-based technique and demonstrated that it consisted of 12q13-q15 sequences fused to DNA sequences derived from 14q23-24 and most likely represented the translocation junction on der(14) in LM-30.1/SV40 cells. Our studies strongly suggest that we have identified and isolated the uterine leiomyoma cluster region of chromosome 12 breakpoints, which we designate ULCR12, and molecularly cloned and characterized the der(14) translocation junction in cells derived from a uterine leiomyoma carrying the frequently observed t(12;14)(q15;q24).

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7529547     DOI: 10.1002/gcc.2870110207

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  5 in total

1.  Genomic analysis of human multigene families using chromosome-specific vectorette PCR.

Authors:  T P Moynihan; A F Markham; P A Robinson
Journal:  Nucleic Acids Res       Date:  1996-10-15       Impact factor: 16.971

2.  HMGI-C expression patterns in human tissues. Implications for the genesis of frequent mesenchymal tumors.

Authors:  P Rogalla; K Drechsler; G Frey; Y Hennig; B Helmke; U Bonk; J Bullerdiek
Journal:  Am J Pathol       Date:  1996-09       Impact factor: 4.307

3.  The fibulin-1 gene (FBLN1) is disrupted in a t(12;22) associated with a complex type of synpolydactyly.

Authors:  P Debeer; E F P M Schoenmakers; W O Twal; W S Argraves; L De Smet; J P Fryns; W J M Van De Ven
Journal:  J Med Genet       Date:  2002-02       Impact factor: 6.318

4.  Cytogenic and molecular analysis of an aggressive angiomyxoma.

Authors:  B Kazmierczak; S Wanschura; K Meyer-Bolte; J Caselitz; P Meister; S Bartnitzke; W Van de Ven; J Bullerdiek
Journal:  Am J Pathol       Date:  1995-09       Impact factor: 4.307

5.  A fibroadenoma with a t(4;12) (q27;q15) affecting the HMGI-C gene, a member of the high mobility group protein gene family.

Authors:  B Staats; U Bonk; S Wanschura; P Hanisch; E F Schoenmakers; W J Van de Ven; S Bartnitzke; J Bullerdiek
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.